Lung Cancer

The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.

It has been a “renaissance” in the non–small cell lung cancer landscape with the rapid evolution of targeted treatment for patients with EGFR-mutation–positive disease, says Edward S. Kim, MD.

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

Ferdinandos Skoulidis, MD, PhD, MRCP, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses combining chemotherapy and immunotherapy in non-small cell lung cancer (NSCLC).

The approach to first-line treatment of advanced non-small cell lung cancer (NSCLC) has been evolving rapidly, particularly with respect to patients with lung adenocarcinoma.

Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses central nervous system penetration in the treatment of non-small cell lung cancer.

Gerard Zalcman, MD, discusses the promise of immunotherapy in patients with mesothelioma.

Marina C. Garassino, MD, discusses the evolving paradigm of immunotherapy in NSCLC, with a specific focus on durvalumab and the role of combination therapy.

George R. Simon, MD, FACP, FCCP, professor of medicine, The University of Texas MD Anderson Cancer Center, discusses durvalumab (Imfinzi) for patients with lung cancer.

H. Jack West, MD, a thoracic oncologist of Swedish Cancer Institute at Swedish Medical Center, discusses the FDA approval of alectinib (Alecensa) as a first-line treatment for patients with ALK-positive, metastatic non–small cell lung cancer (NSCLC).

The FDA has approved alectinib (Alecensa) for the frontline treatment of patients with ALK-positive metastatic non-small cell lung cancer.

Frank E. Mott, MD, FACP, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses taregeted therapy for ALK-positive non-small cell lung cancer (NSCLC).